Clinical Trials Logo

Clinical Trial Summary

This is a randomized pharmacological study evaluating the effects of ivabradine in patients with residual angina after PCI. The role of ivabradine in patients with angina, without systolic dysfunction, is not yet clear. The investigators performed in all patients an echostress to evaluate the effects of therapy with ivabradine after 30 days in terms of exercise tolerance and diastolic function.

Clinical Trial Description

BACKGROUND. Residual angina after PCI is a frequently-occurring disease. Ivabradine improves symptoms but its role in patients without left-ventricular systolic dysfunction is still unclear. The aim was to quantify the effects of ivabradine in terms of MVO2 indicators and diastolic function.

METHODS. 28 consecutive patients with residual angina after PCI were randomized to ivabradine 5 mg twice/day(IG) or standard therapy(CG). All patients performed a stress echocardiography at the enrollment and after 30 days. Myocardial oxygen consumption was estimated from: double product(DP); triple product(TP) integrating DP with ejection-time(ET). Diastolic function was evaluated determining E and A waves, E' measurements and E/E' ratio both at rest and at the peak of exercise. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03866395
Study type Interventional
Source Azienda Policlinico Umberto I
Status Completed
Phase Phase 4
Start date March 5, 2015
Completion date March 7, 2017

See also
  Status Clinical Trial Phase
Completed NCT01826994 - Incremental Value of Point of Care H-FABP Testing in Primary Care Patients Suspected of Acute Coronary Syndrome N/A
Recruiting NCT02710435 - REDUCER-I: An Observational Study of the Neovasc Reducerâ„¢ System